Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 3/20 | 1.00 |
| ▸ | HTR2B | P41595 | 3/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | AR | P10275 | 2/20 | 1.00 |
| ▸ | LCK | P06239 | 2/20 | 1.00 |
| ▸ | FYN | P06241 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | MAPK3 | P27361 | 2/20 | 1.00 |
| ▸ | HTR2C | P28335 | 2/20 | 1.00 |
| ▸ | DRD3 | P35462 | 2/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | HRH2 | P25021 | 1/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tirilazad SCHEMBL25994341 | 1.00 | PGR (1.00) | PGRHTR2BKCNH2ARLCK | |
| Tirilazad SCHEMBL483318 | 1.00 | PGR (1.00) | PGRHTR2BKCNH2ARLCK | |
| SCHEMBL9134229 | 1.00 | PGR (1.00) | PGRHTR2BKCNH2ARLCK | |
| Tirilazad SCHEMBL9073226 | 0.99 | PGR (0.99) | PGRHTR2BKCNH2ARLCK | |
| Tirilazad SCHEMBL9073229 | 0.99 | PGR (0.99) | PGRHTR2BKCNH2ARLCK | |
| Tirilazad SCHEMBL10695568 | 0.97 | KCNH2 (0.93) | PGRHTR2BKCNH2ARLCK | |
| Tirilazad SCHEMBL9724980 | 0.97 | KCNH2 (0.93) | PGRHTR2BKCNH2ARLCK | |
| Tirilazad SCHEMBL1650168 | 0.97 | KCNH2 (0.93) | PGRHTR2BKCNH2ARLCK | |
| Tirilazad SCHEMBL9069954 | 0.97 | KCNH2 (0.93) | PGRHTR2BKCNH2ARLCK | |
| Tirilazad SCHEMBL9221827 | 0.97 | KCNH2 (0.93) | PGRHTR2BKCNH2ARLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023154647-A1 | COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF DISEASES UTILIZING TIRILAZAD SALTS | PRENDERGAST PATRICK T (IE) | 2023-08-17 | — | — | WO | claimed |
| US-20050054646-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an antioxidant agent for the treatment of central nervous system disorders | PHARMACIA CORPORATION | 2005-03-10 | — | — | US | claimed |
| WO-2005016243-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND AN ANTIOXIDANT AGENT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | PHARMACIA CORPORATION (US) | 2005-02-24 | — | — | WO | claimed |
| EP-0778775-B1 | COSOLVENT PARENTERAL FORMULATION OF TIRILAZAD | UPJOHN CO (US) | 1999-01-20 | — | — | EP | claimed |
| EP-0660717-B1 | AMINOSTEROIDS FOR OPHTHALMIC USE | INSITE VISION INC (US) | 1998-03-11 | — | — | EP | claimed |
| US-5538721-A | LIGHTLY CROSSLINKED CARBOXY POLYMER | INSITE VISION INCORPORATED (US) | 1996-07-23 | — | — | US | claimed |
| EP-0674528-A4 | CYCLODEXTRIN AND POLYMER BASED DRUG DELIVERY SYSTEM. | INSITE VISION INC (US) | 1996-06-26 | — | — | EP | claimed |
| EP-0238545-B1 | C20 THROUGH C26 AMINO STEROIDS | UPJOHN CO (US) | 1995-11-15 | — | — | EP | claimed |
| EP-0674528-A1 | CYCLODEXTRIN AND POLYMER BASED DRUG DELIVERY SYSTEM | INSITE VISION INCORPORATED (US) | 1995-10-04 | — | — | EP | claimed |
| EP-0263213-B1 | C20 Through C26 amino steroids | UPJOHN CO (US) | 1995-09-06 | — | — | EP | claimed |
| US-5332582-A | Lightly crosslinked carboxy-containing polymers | INSITE VISION INCORPORATED (US) | 1994-07-26 | — | — | US | claimed |
| WO-1994012217-A1 | CYCLODEXTRIN AND POLYMER BASED DRUG DELIVERY SYSTEM | INSITE VISION INCORPORATED (US) | 1994-06-09 | — | — | WO | claimed |
| US-5175281-A | Antiulcer, antiinflammatory, antiischemic, antiallergen, antisecretory, wound healing agents; cardiovascular disorders | THE UPJOHN COMPANY (US) | 1992-12-29 | — | — | US | claimed |
| EP-0263213-A1 | C20 Through C26 amino steroids | THE UPJOHN COMPANY (US) | 1988-04-13 | — | — | EP | claimed |
| EP-0238545-A1 | C 20? THROUGH C 26? AMINO STEROIDS. | UPJOHN CO (US) | 1987-09-30 | — | — | EP | claimed |
| WO-1987001706-A2 | C20 THROUGH C26 AMINO STEROIDS | THE UPJOHN COMPANY (US) | 1987-03-26 | — | — | WO | claimed |
| WO-2023154647-A1 | COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF DISEASES UTILIZING TIRILAZAD SALTS | PRENDERGAST PATRICK T (IE) | 2023-08-17 | — | — | WO | disclosed |
| US-8486374-B2 | Alcohol-free drug or cosmetics carrier mixture of water, hydrophobic solvent, surfactant and gelling agent; oil in water emulsions | FOAMIX LTD. (IL) | 2013-07-16 | — | — | US | disclosed |
| EP-0238545-A1 | C 20? THROUGH C 26? AMINO STEROIDS. | UPJOHN CO (US) | 1987-09-30 | — | — | EP | disclosed |
| WO-1987001706-A2 | C20 THROUGH C26 AMINO STEROIDS | THE UPJOHN COMPANY (US) | 1987-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054646-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an antioxidant agent for the treatment of central nervous system disorders | TXNRD2, PRDX5, PTGS2 | PGR 3350/4885HTR2B 582/4885KCNH2 4139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.